肝脏 ›› 2019, Vol. 24 ›› Issue (8): 871-874.

• 论著 • 上一篇    下一篇

永生化肝脏前体样细胞可用于生物人工肝治疗的研究

李伟建, 王振宇, 袁天杰, 景宏舒, 代孟君, 彭媛, 鄢和新, 翟博   

  1. 200127 上海交通大学医学院附属仁济医院肿瘤介入科(李伟建,王振宇,景宏舒,代孟君,彭媛,鄢和新,翟博),麻醉科(袁天杰)
  • 收稿日期:2019-04-16 发布日期:2020-04-01
  • 通讯作者: 鄢和新,Email:hexinyw@163.com;翟博,Email:Zhaiboshi@sina.com
  • 基金资助:
    国家科技重大专项课题(2017ZX10203206-006-002)

The study of immortalized hepatocyte-derived liver progenitor-like cells used in bioartificial liver therapy

LI Wei-jian1, WANG Zhen-yu1, YUAN Tian-jie2, JING Hong-shu1, DAI Meng-jun1, PENG Yuan1, YAN He-xin1,2, ZHAI Bo1   

  1. 1. Department of Interventional Oncology, Renji Hospital, Jiaotong University School of Medicine, Shanghai 200127, China;
    2. Department of Anesthesiology and Critical Care Medicine, Renji Hospital, Jiaotong University School of Medicine, Shanghai 200127, China
  • Received:2019-04-16 Published:2020-04-01
  • Contact: YAN He-xin, Email: hexinyw@163.com; ZHAI Bo, Email: Zhaiboshi@sina.com

摘要: 目的 对肝前体样细胞(hepatocyte-derived liver progenitor-like cells,HepLPC)进行功能验证,为生物人工肝应用寻找新的种子细胞。方法 通过两步分离法分离人原代肝细胞,荧光激活细胞分选术纯化肝细胞以排除CD24 +或EpCAM +阳性祖细胞获得HepLPC,采用Large T 抗原对HepLPC进行永生化(iHepLPC),从细胞形态、增殖状态、功能基因水平、解毒与合成水平以及急性肝衰竭毒性血浆的反应对iHepLPC进行综合评估,判断其是否具有相应的功能。结果 永生化后iHepLPC可以在不同代次间快速稳定的增殖,P0、P10与P20代次之间同一时间点细胞的增殖速度相似,差异无统计学意义(P>0.05),细胞形态保持不变,增殖过程中的细胞解毒与合成功能稳定,代次之间差异无统计学意义(P>0.05);对iHepLPC细胞进行M7分化,分化后细胞的功能基因有显著的提高,尿素生成(13.683±1.238)高于未分化的7.769±0.323(P<0.01);分化后白蛋白合成11.270±0.63,高于未分化的5.655±0.025(P<0.01);对于急性肝衰竭血浆具有一定的耐受力同时发挥着解毒与合成功能,6 h候后尿素合成达到(8.25±0.31)mg/(dL·106细胞·d),白蛋白合成达到(12±0.41)ng/(mL·106细胞·d)。结论 永生化后的HepLPC在快速增殖的过程中可以保持细胞形态、解毒与合成功能不变,对急性肝衰竭血浆具有一定的耐受力是新的生物人工肝细胞源。

关键词: 肝前体样细胞, 永生化, 生物人工肝, 急性肝衰竭

Abstract: Objective To verify the function of hepatocyte-derived liver progenitor-like cells (HepLPCs), and to find new seed cells for bioartificial liver application.Methods Human primary hepatocytes were isolated by 2-step separation method, and hepatocytes were purified by fluorescence activated cell sorting to exclude HepLPCs from cluster of differentiation 24 + or epithelial cell adhesion molecule + progenitor cells. HepLPCs were immortalized by large T antigen. Then, cell morphology, proliferation states, functional gene levels, detoxification and synthesis levels, and responses to acute hepatic failure (AHF) toxic plasma of immortalized HepLPCs (iHepLPCs) were comprehensively evaluated. Results After immortalization, iHepLPCs could proliferate rapidly and stably in different passages. There was no significant difference in the proliferation rates of passage 0, passage 10 and passage 20 at the same time point (P>0.05), and the cell morphology remained unchanged. The cell detoxification and synthesis functions were stable during the proliferation process, and there was no significant difference among passages (P>0.05). Besides, the differentiation of iHepLPCs cells significantly enhanced expression of the functional genes. The urea production of differentiated iHepLPCs cells was higher than that of undifferentiated ones (13.683±1.238 vs 7.769±0.323, P<0.005). Also, albumin synthesis of differentiated iHepLPCs cells was higher than that of undifferentiated ones (11.270±0.63 vs 5.565±0.025, P<0.005). Furthermore, differentiated iHepLPCs cells had certain tolerance to AHF plasma with detoxification and synthesis abilities. After 6-hour culture in AHF plasma, urea synthesis reached 8.25±0.31, and albumin synthesis reached 12±0.41.Conclusion The iHepLPCs have certain tolerance to AHF plasma, whose cell morphology, detoxification and synthesis functions maintain stable in the process of rapid proliferation. Therefore, iHepLPCs could be a new source of bioartificial hepatocytes.

Key words: Hepatocyte-derived liver progenitor-like cells, Immortalization, Bioartificial liver, Acute liver failure